Trial Profile
A prospective, phase II study of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, doxorubicin, vincristine and dexamethasone alternated with bortezomib, rituximab, cytarabine and methotrexate in patients with newly diagnosed mantle cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 14 May 2018 New trial record
- 03 May 2018 Results published in the Cancer